By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Trimethobenzamide (monograph)
Drugs

Trimethobenzamide (monograph)

https://themeditary.com/drug/trimethobenzamide-monograph-5769.html
Medically Reviewed by Oluni Odunlami, MD TheMediTary.Com | Reviewed: Aug 12, 2023  Additional Content by TheMediTary.Com

Generic name: tigan

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Brand names: Tigan (oral/injection), Trimethobenzamide (oral/injection)

Contents
Uses Warnings Before Taking Dosage Side effects Interactions
  • Trimethobenzamide (monograph) (Tigan)-MUTUAL 401 MUTUAL 401-300 mg-Orange-Capsule-shape Trimethobenzamide (monograph) 300 mg (MUTUAL 401 MUTUAL 401)
  • Trimethobenzamide (monograph) (Tigan)-A185-300 mg-Purple-Capsule-shape Trimethobenzamide (monograph) 300 mg (A185)
  • Trimethobenzamide (monograph) (Tigan)-Novel 660 300 mg-300 mg-Purple-Capsule-shape Trimethobenzamide (monograph) 300 mg (Novel 660 300 mg)
  • View all images

What is Trimethobenzamide (monograph)?

Introduction

Antiemetic agent.

Uses for Trimethobenzamide

Nausea and Vomiting

Control of nausea and vomiting, including treatment of postoperative nausea and vomiting.

Treatment of nausea associated with gastroenteritis.

Less effective than phenothiazines, but may be associated with fewer adverse effects.

Trimethobenzamide Dosage and Administration

Administration

Administer orally or by IM injection.

Not recommendedfor IV administration.

Preparation for rectal administration is no longer commercially available in the US; FDA has withdrawn approval of the new drug application (NDA) for the rectal suppositories because of lack of substantial evidence of efficacy. (See Preparations.)

IM Administration

Minimize local adverse effects by injecting deep into the upper outer quadrant of the gluteus maximus; avoid local infiltration of the solution along the needle track.

Dosage

Available as trimethobenzamide hydrochloride; dosage expressed in terms of the salt.

Pediatric Patients

Nausea and Vomiting
Oral

Children weighing 13.6–45 kg: 100 or 200 mg 3 or 4 times daily; alternatively, children may receive 15–20 mg/kg daily given in 3 or 4 divided doses. However, suitable oral dosage forms are no longer commercially available in the US.

Adults

Nausea and Vomiting
Oral

Usual dosage: 300 mg 3 or 4 times daily. Adjust dosage according to indication for use, severity of symptoms, and patient response.

IM

Usual dosage: 200 mg 3 or 4 times daily. Adjust dosage according to indication for use, severity of symptoms, and patient response.

Special Populations

No special population dosage recommendations at this time.

Detailed Trimethobenzamide dosage information

Related/similar drugs

hydroxyzine, ondansetron, lorazepam, meclizine, Benadryl, promethazine

Warnings

Contraindications

  • Known hypersensitivity to trimethobenzamide.

  • Injection contraindicated in children.

Warnings/Precautions

Warnings

CNS Depression

May impair ability to perform activities requiring mental alertness or physical coordination (e.g., operating machinery, driving a motor vehicle); avoid concomitant use with alcohol.

Neurologic Effects

Possible neurologic reactions (e.g., opisthotonos, seizures, coma, extrapyramidal reactions); may be similar to CNS signs and symptoms accompanying certain disorders (e.g., acute febrile illness, encephalitis, Reye’s syndrome, encephalopathy, gastroenteritis, dehydration, electrolyte imbalance), especially in children and in geriatric or debilitated patients. Diagnosis of these disorders may be obscured or the disease-associated signs and symptoms may be incorrectly diagnosed as drug induced.

Use with caution in patients with such disorders, particularly in those who have recently received other CNS drugs (e.g., phenothiazines, barbiturates, belladonna derivatives). (See Specific Drugs under Interactions.)

Avoid use in pediatric patients with signs and symptoms suggestive of Reye’s syndrome. (See Pediatric Use under Cautions.)

Discontinue drug if CNS symptoms occur.

Sensitivity Reactions

Hypersensitivity Reactions

Hypersensitivity reactions including allergic skin reactions have been reported; discontinue at the first sign of sensitization.

General Precautions

Hepatic Effects

Jaundice reported; discontinue drug if jaundice occurs.

Potential hepatotoxic effects may unfavorably alter the course of Reye’s syndrome. (See Pediatric Use under Cautions.)

Hematologic Effects

Blood dyscrasias reported; discontinue drug if blood dyscrasia occurs.

GI Effects

Antiemetic effect may mask signs of overdosage of other drugs or may obscure the cause of vomiting in various disorders (e.g., appendicitis).

Discontinue drug if exaggeration of preexisting nausea occurs.

Specific Populations

Pregnancy

Category C.

Lactation

Not known whether trimethobenzamide is distributed into milk. Safety not established.

Pediatric Use

Injection contraindicated in children. Suitable oral dosage forms and rectal suppositories for pediatric use no longer are commercially available in the US. (See Preparations.)

Use trimethobenzamide with caution in children. Not recommended for treatment of uncomplicated vomiting in children; limit use to treatment of prolonged vomiting of known etiology. Avoid use in pediatric patients with signs and symptoms suggestive of Reye’s syndrome.

Extrapyramidal effects of trimethobenzamide may obscure the diagnosis of or be confused with CNS manifestations of Reye’s syndrome or other encephalopathies. (See Neurologic Effects under Cautions.)

Potential hepatotoxic effects of trimethobenzamide may unfavorably alter the course of Reye’s syndrome.

Children with acute febrile illnesses, encephalitides, gastroenteritis, dehydration, or electrolyte imbalance may be at increased risk for adverse CNS effects (e.g., extrapyramidal reactions, opisthotonos, seizures, coma). Use with caution in such children, especially those who recently have received other CNS agents.

Geriatric Use

Geriatric and debilitated patients with acute febrile illnesses, encephalitides, gastroenteritis, dehydration, or electrolyte imbalance may be at increased risk for adverse CNS effects (e.g., extrapyramidal reactions, opisthotonos, seizures, coma). Use with caution in such individuals, especially those who recently have received other CNS agents.

Common Adverse Effects

Adverse effects may include blurred vision, depression, disorientation, dizziness, drowsiness, headache, extrapyramidal symptoms, diarrhea, opisthotonos, and muscle cramps. In addition, injection site reactions (pain, stinging, redness, swelling ) and hypotension may occur following IM injection.

How should I use Trimethobenzamide (monograph)

Administration

Administer orally or by IM injection.

Not recommendedfor IV administration.

Preparation for rectal administration is no longer commercially available in the US; FDA has withdrawn approval of the new drug application (NDA) for the rectal suppositories because of lack of substantial evidence of efficacy. (See Preparations.)

IM Administration

Minimize local adverse effects by injecting deep into the upper outer quadrant of the gluteus maximus; avoid local infiltration of the solution along the needle track.

Dosage

Available as trimethobenzamide hydrochloride; dosage expressed in terms of the salt.

Pediatric Patients

Nausea and Vomiting
Oral

Children weighing 13.6–45 kg: 100 or 200 mg 3 or 4 times daily; alternatively, children may receive 15–20 mg/kg daily given in 3 or 4 divided doses. However, suitable oral dosage forms are no longer commercially available in the US.

Adults

Nausea and Vomiting
Oral

Usual dosage: 300 mg 3 or 4 times daily. Adjust dosage according to indication for use, severity of symptoms, and patient response.

IM

Usual dosage: 200 mg 3 or 4 times daily. Adjust dosage according to indication for use, severity of symptoms, and patient response.

Special Populations

No special population dosage recommendations at this time.

Detailed Trimethobenzamide dosage information

Related/similar drugs

hydroxyzine, ondansetron, lorazepam, meclizine, Benadryl, promethazine
Trimethobenzamide (monograph) Dosage information (more detail)

What other drugs will affect Trimethobenzamide (monograph)?

Specific Drugs

Drug

Interaction

Comments

Alcohol

Impaired mental alertness/physical coordination

Avoid concomitant use

CNS drugs (e.g., barbiturates, belladonna derivatives, phenothiazines)

Possible increased risk of CNS reactions

Use with caution

More about Trimethobenzamide (monograph) (Tigan)

Dosage information
Trimethobenzamide (monograph) Side Effects
During pregnancy
Trimethobenzamide Capsules Prescribing Information
Drug images
Side effects
Breastfeeding Warnings
Drug class: Drugs

Related treatment guides

Nausea/Vomiting
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by